Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.

NEKTAR THERAPEUTICS

Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.
Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.
Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.
Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.